Weathering The Storm: Cell And Gene's Economic Downturn

By James Wilson and Anshul Mangal

When faced with a market downturn, business leaders are forced to conserve cash, make difficult choices, and consider mitigating actions like forced layoffs and the suspension of crucial product programs, which ultimately jeopardize the advancement of the industry. Stretching capital can also be accomplished by divesting from undesirable assets, such as pointless manufacturing facilities.

Following record-setting milestones in fundraising over the past two years, however, the advanced therapy investment landscape is experiencing a natural correction and has returned to pre-pandemic numbers. And while programs serving smaller patient populations were sidelined during the economic downturn, leaders of the advanced medicines industry and champions of patients with rare diseases are dedicated to ensuring these programs weathered the financial storm.

Precision’s Anshul Mangal and Dr. James M. Wilson outline how industry leaders can ensure the advancement of innovative treatments for patients with rare diseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.